Last reviewed · How we verify
K-924 LD
K-924 LD is a Dopamine D2/D3 receptor agonist Small molecule drug developed by Kowa Company, Ltd.. It is currently in Phase 3 development for Parkinson's disease.
K-924 LD is a long-acting dopamine D2/D3 receptor agonist designed to provide sustained dopaminergic activity for extended treatment intervals.
K-924 LD is a treatment being studied in a Phase III clinical trial for hypercholesterolemia. The trial, NCT04289649, is a randomized, multicenter study comparing K-924 LD to a placebo.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | K-924 LD |
|---|---|
| Sponsor | Kowa Company, Ltd. |
| Drug class | Dopamine D2/D3 receptor agonist |
| Target | Dopamine D2 receptor, Dopamine D3 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
K-924 LD acts as a dopamine receptor agonist with affinity for D2 and D3 receptors, formulated as a long-acting depot or extended-release preparation to enable less frequent dosing. This mechanism is intended to improve treatment adherence and maintain consistent dopaminergic signaling in conditions where dopamine deficiency or dysregulation is pathogenic.
Approved indications
- Parkinson's disease
Common side effects
- Nausea
- Dizziness
- Somnolence
- Orthostatic hypotension
Key clinical trials
- K-924 Phase III Confirmatory Study (PHASE3)
- K-924 Phase III Long Term Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- K-924 LD CI brief — competitive landscape report
- K-924 LD updates RSS · CI watch RSS
- Kowa Company, Ltd. portfolio CI
Frequently asked questions about K-924 LD
What is K-924 LD?
How does K-924 LD work?
What is K-924 LD used for?
Who makes K-924 LD?
What drug class is K-924 LD in?
What development phase is K-924 LD in?
What are the side effects of K-924 LD?
What does K-924 LD target?
Related
- Drug class: All Dopamine D2/D3 receptor agonist drugs
- Target: All drugs targeting Dopamine D2 receptor, Dopamine D3 receptor
- Manufacturer: Kowa Company, Ltd. — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Parkinson's disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing